Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price objective hoisted by Canaccord Genuity Group from $121.00 to $136.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target would suggest a potential upside of 207.07% from the stock’s previous […]
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price objective hoisted by Canaccord Genuity Group from $121.00 to $136.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target would suggest a potential upside of 207.07% from the stock’s previous […]
